ClinicalTrials.gg
CompletedNCT06834789Updated Nov 17, 2025

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

A Phase 1 interventional study of AGN-151586 and OnabotulinumtoxinA in Glabellar Lines, sponsored by AbbVie. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).

02

Conditions studied

  • Glabellar Lines

Keywords

  • Glabellar Lines
  • AGN-151586
  • OnabotulinumtoxinA
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has moderate or severe glabellar lines (GL) at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS).
  • Must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, 12-lead parameters, clinical laboratory evaluations, and neurological assessment.

Exclusion criteria

Exclusion Criteria:

  • Active infection or dermatological condition at the treatment injection sites.
  • History of immunization to any botulinum neurotoxin serotype or to any botulinum neurotoxin serotype or any other constituents of the study drug or its , and/or other products in the same class.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Cohort 1: AGN-151586 Dose A and OnabotulinumtoxinA

    Participants will receive a single treatment of AGN-151586 Dose A and OnabotulinumtoxinA.

    Drug: AGN-151586 · Drug: OnabotulinumtoxinA

  • Experimental
    Cohort 2: AGN-151586 Dose B and OnabotulinumtoxinA

    Participants will receive a single treatment of AGN-151586 Dose B and OnabotulinumtoxinA.

    Drug: AGN-151586 · Drug: OnabotulinumtoxinA

  • Experimental
    Cohort 3: AGN-151586 Dose A and OnabotulinumtoxinA

    Participants will receive a single treatment of AGN-151586 Dose A and OnabotulinumtoxinA.

    Drug: AGN-151586 · Drug: OnabotulinumtoxinA

  • Experimental
    Cohort 3: AGN-151586 Dose B and OnabotulinumtoxinA

    Participants will receive a single treatment of AGN-151586 Dose B and OnabotulinumtoxinA.

    Drug: AGN-151586 · Drug: OnabotulinumtoxinA

  • Experimental
    Cohort 3: Placebo and OnabotulinumtoxinA

    Participants will receive a single treatment of Placebo and OnabotulinumtoxinA.

    Drug: OnabotulinumtoxinA · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 10.4 months

  2. Number of Participants with the Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586 and/or OnabotulinumtoxinA

    Samples collected from participants treated with AGN-151586 and OnabotulinumtoxinA will be analyzed for antibodies against both AGN-151586 and OnabotulinumtoxinA.

    Time frame: Up to approximately 10.4 months

07

Study locations

8 sites
  • Investigate MD /ID# 270771
    Scottsdale, Arizona 85260, United States
  • Eye Research Foundation /ID# 270827
    Newport Beach, California 92663, United States
  • Marcus Facial Plastic Surgery /ID# 270770
    Redondo Beach, California 90277, United States
  • Skin Research Institute LLC /ID# 270831
    Coral Gables, Florida 33146-1837, United States
  • Skincare Physicians /ID# 271018
    Chestnut Hill, Massachusetts 02467, United States
  • Wilmington Dermatology Center /ID# 270828
    Wilmington, North Carolina 28403, United States
  • Austin Institute for Clinical Research - Pflugerville /ID# 270834
    Pflugerville, Texas 78660, United States
  • SkinDC /ID# 270932
    Arlington, Virginia 22209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Nov 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 19, 2025
StartActual
Feb 18, 2025
Primary completionActual
Nov 3, 2025
CompletionActual
Nov 3, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06834789
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Feb 18, 2025
Primary completion
Nov 3, 2025
Completion
Nov 3, 2025
Last update
Nov 17, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: trenibotulinumtoxinE

Start the discussion